One such NR is the liver receptor homolog 1 (LRH‐1, a.k.a. NR5A2), which has emerged as a promising drug target for diseases like diabetes, pancreatic cancer, non‐alcoholic fatty liver disease and metabolic syndrome.13, 14, 15, 16, 17, 18. This evidence concerns the gene NR5A2 and familial pancreatic carcinoma.